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Blood pressure-lowering effects of nifedipine/candesartan
combinations in high-risk individuals: subgroup analysis
of the DISTINCT randomised trial
G Mancia1, G Cha2, B Gil-Extremera3, P Harvey4, AJ Lewin5, G Villa6 and SE Kjeldsen7 for the DISTINCT Investigators
The DISTINCT study (reDefining Intervention with Studies Testing Innovative Nifedipine GITS—Candesartan Therapy) investigated
the efficacy and safety of nifedipine GITS/candesartan cilexetil combinations vs respective monotherapies and placebo in patients
with hypertension. This descriptive sub-analysis examined blood pressure (BP)-lowering effects in high-risk participants, including
those with renal impairment (estimated glomerular filtration rateo90 ml min− 1, n= 422), type 2 diabetes mellitus (n= 202),
hypercholesterolaemia (n= 206) and cardiovascular (CV) risk factors (n= 971), as well as the impact of gender, age and body mass
index (BMI). Participants with grade I/II hypertension were randomised to treatment with nifedipine GITS (N) 20, 30, 60 mg and/or
candesartan cilexetil (C) 4, 8, 16, 32 mg or placebo for 8 weeks. Mean systolic BP and diastolic BP reductions after treatment in
high-risk participants were greater, overall, with N/C combinations vs respective monotherapies or placebo, with indicators of a
dose–response effect. Highest rates of BP control (ESH/ESC 2013 guideline criteria) were also achieved with highest doses of N/C
combinations in each high-risk subgroup. The benefits of combination therapy vs monotherapy were additionally observed in
patient subgroups categorised by gender, age or BMI. All high-risk participants reported fewer vasodilatory adverse events in the
pooled N/C combination therapy than the N monotherapy group. In conclusion, consistent with the DISTINCT main study
outcomes, high-risk participants showed greater reductions in BP and higher control rates with N/C combinations compared with
respective monotherapies and lesser vasodilatory side-effects compared with N monotherapy.
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INTRODUCTION
Individuals with hypertension who have comorbidities such as
diabetes mellitus, renal impairment or established cardiovascular
(CV) disease are at increased risk of future events and mortality.1–4
Prompt initiation of treatment is recommended in individuals
with grade 2 or 3 hypertension and any level of CV risk2,5 because
a short time-to-effect has been demonstrated between increased
blood pressure (BP) control and reduction in CV risk.6 To achieve
an optimal time-to-effect, many guidelines recommend initial
combination therapy using agents that have complementary
mechanisms of action.2,7
Angiotensin II is known to have a role in the progression of
diabetic nephropathy.8 Recent guidelines recommended
initiating therapy including a renin angiotensin system (RAS)
blocker in patients with chronic kidney disease (CKD) owing to
beneficial renal outcomes.2,7 Unlike β-blockers or diuretics,
calcium channel blockers (CCB) are not associated with adverse
effects on glucose and lipid metabolism7,9 and, thus, are not
considered of concern in patients with diabetes or metabolic
syndrome. Furthermore, the combination of a CCB with a RAS
blocker has the potential for greater BP reductions compared with
monotherapy, especially in high-risk patients in whom BP control
is more difficult,2 can reduce peripheral oedema (vs CCB
monotherapy)10,11 and attenuate renal hyperfiltration.12
Although a number of angiotensin receptor blocker (ARB)–CCB
fixed-dose combinations are available, none have previously
contained the extended-release formulation of nifedipine GITS.
The potential benefits of a nifedipine GITS–ARB combination
in high-risk patients is, therefore, clinically interesting. DISTINCT
(reDefining Intervention with Studies Testing Innovative
Nifedipine GITS—Candesartan Therapy) was an 8-week,
randomised, double-blind, placebo-controlled, parallel-group,
multifactorial study that evaluated the efficacy and safety of dose
combinations of nifedipine GITS and candesartan cilexetil,
compared with respective monotherapies and placebo, in patients
with grade 1 or 2 hypertension.11 In DISTINCT, the ARB–CCB
combination was effective and well tolerated, with each
component contributing independently to BP reductions; the
combination also significantly reduced vasodilatory side-effects
compared with nifedipine GITS monotherapy.
The current descriptive subgroup analyses of DISTINCT inves-
tigated the BP-lowering effects and tolerability of nifedipine
GITS–candesartan cilexetil combinations in high-risk participants,
including those with renal impairment, type 2 diabetes mellitus
(T2DM), hypercholesterolaemia and an aggregate of CV risk factors
(T2DM or body mass index (BMI)⩾ 30 kg m− 2 or low-density
lipoprotein (LDL) cholesterol⩾ 130 mg dl− 1), as well as assessing
the effects of gender, age and BMI.
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METHODS
Study design
Details of the DISTINCT study design have been reported previously11
(clinicaltrials.gov identifier NCT01303783). In brief, DISTINCT was an
8-week, multi-national, multi-centre, randomised, double-blind, placebo-
controlled, multifactorial study to determine the dose–response of 16
combinations of nifedipine GITS (N) 0, 20, 30 or 60 mg and/or candesartan
cilexetil (C) 0, 4, 8, 16 or 32 mg in participants with grade 1 and 2
hypertension. Following a 2-week (±3 days) screening/washout period and
a 2–4 week, single-blind, placebo run-in, participants were randomised in
equal ratios to one of the 16 treatment groups. For subjects randomised to
the highest dose (N60C32), there was a forced dose titration period of one
week, during which N30C16 was administered. Subjects were instructed to
take their medication with water at the same time in the morning
(8:00 ± 2 h), except on the day of a visit.
The study was conducted in accordance with the Declaration of Helsinki
and the International Conference on Harmonization guidelines on good
clinical practice. The study protocol was reviewed and approved by each
centre’s independent ethics committee or institutional review board. All
participants provided written informed consent prior to study entry.
Standardsation across investigator sites was maintained by establishment
of a detailed clinical protocol and through monitoring adherence to the
protocol by COVANCE Inc. (Indianapolis, IN, USA).
Population
DISTINCT included men and women aged 18 years or older with grade 1 or
2 hypertension according to the World Health Organization/International
Society of Hypertension 2003 guidelines.13 Patients were recruited from
131 study centres in 12 countries (Argentina, Belgium, Canada, Italy,
Lithuania, Russia, South Africa, South Korea, Spain, Ukraine, UK and USA)
between 28 April 2011 and 28 May 2012.11 BP was measured by a
calibrated electronic device (Model HEM-705CP; Omron Healthcare, Inc.,
Bannockburn, IL, USA), with a cuff of appropriate size, supplied with
instructions for use by Bayer HealthCare AG (Berlin, Germany). Patients
were required to have a mean seated diastolic BP (DBP)⩾ 95 mm Hg and
o110 mm Hg at randomisation, and an absolute difference in mean
seated DBP of o10 mm Hg between screening and randomisation,
consistent with the guidelines current at the time of study planning and
in agreement with other phase IIb dose-finding studies of CCB/ARB fixed-
dose agents (for example, amlodipine/valsartan, amlodipine/olmesartan
and amlodipine/telmisartan).13–16 Inclusion and exclusion criteria have
been described previously.11
The current subgroup analysis focuses on BP lowering in participants in
DISTINCT with renal impairment, T2DM, hypercholesterolaemia and CV risk
factors, as well as patients categorised by gender, age and BMI. Renal
impairment was defined by an estimated glomerular filtration rate (eGFR)
o60 ml min− 1 (that is, moderate/severe) and o90 ml min− 1 (that is, any
grade of renal impairment) at baseline.17,18 Hypercholesterolaemia was
defined as total cholesterol4240 mg dl− 1.2,19 CV risk factors were defined
as T2DM, BMI⩾ 30 kg m− 2 (obesity), LDL cholesterol⩾ 130 mg dl− 1 or any
combination of these factors.20 The potential impacts of age and BMI were
assessed by analysis of tertiles (age:o55, 55–64 and ⩾ 64 years; BMI:o25,
25–29 and ⩾ 30 kg m− 2). Analyses of specific high-risk groups (that is, renal
impairment and T2DM) were prespecified in the study protocol; additional
analyses were performed post hoc.11
Assessments
Visits during the double-blind treatment period were at 1, 2, 4, 6 and
8 weeks post-baseline. BP was measured between 08:00 and 09:00 h. BP
measurements were performed in both arms at first visit and the arm with
highest BP reading was used for all subsequent measurements. At each
visit, patients were required to sit for at least 5 min, after which three
BP measurements were taken 2 min apart, always with the patient in
the seated position. The arithmetic mean BP was considered to be the
representative value of the visit.
The prespecified measurements of interest were: (1) Change from
baseline in mean seated DBP and systolic BP (SBP) and (2) BP control rate
after 8 weeks of treatment. BP control was defined as the proportion of
patients achieving a BP of o140/90 mm Hg, with the exception of
participants with T2DM in any high-risk group, whose control rate was
based on o140/85 mm Hg to reflect recommendations in the latest ESH/
ESC guidelines.2 Control rates are also presented based on BPo130-
/80 mm Hg at 8 weeks in patients with renal impairment or T2DM, as
recommended by ESH/ESC guidelines at the time of study.21
Prespecified analyses of participants with renal impairment in
DISTINCT included a cutoff for eGFR of o60 ml min− 1 (representing
moderate/severe renal impairment). Post hoc analyses in the current paper
additionally include an eGFR cutoff of o90 ml min− 1 (that is, all grades of
renal impairment) to provide increased numbers of patients for analysis
and greater scope for generalisation.
Treatment-emergent adverse events (AE) and their relationship to
treatment were recorded in all groups. The occurrence and severity of
peripheral oedema were assessed at all scheduled visits. Incidences of
headache were determined by participant self-reports.
Statistical analyses
Efficacy analyses in the DISTINCT main study included all randomised
subjects who received at least one dose of study medication and had a
baseline as well as at least one valid post-baseline BP measurement
(‘full analysis set’). The current efficacy analyses included all subjects in the
full analysis set who had the identified risk factors at baseline. Patients in
the full analysis set without these risk factors were also analysed for
Table 1. Baseline characteristics of high-risk and non-high-risk individuals (safety analysis set)
Characteristic Renal impairment of any
grade (baseline
eGFRo90 ml min− 1)
T2DM Hypercholesterolaemia (total
cholesterol 4240 mg dl− 1)
CV risk factor(s) (T2DM or BMI⩾ 30 kg m− 2 or
LDL⩾ 130 mg dl− 1)
Yes
(N= 426)
No
(N= 955)
Yes
(N= 205)
No
(N= 1176)
4240
(N= 210)
200–240
(N= 454)
o200
(N= 715)
1–3
(N= 986)
1–2
(N= 958)
1
(N= 679)
None
(N= 395)
Age, years, mean 61.6 50.6 56.8 53.5 55.2 54.0 53.7 53.7 53.7 53.4 54.8
Male, n (%) 232 (54.5%) 567 (59.4%) 116 (56.6%) 683 (58.1%) 110 (52.4%) 245 (54.0%) 442 (61.8%) 547 (55.5%) 534 (55.7%) 390 (57.4%) 252 (63.8%)
Ethnicity
White, n (%) 317 (74.4%) 685 (71.7%) 148 (72.2%) 854 (72.6%) 166 (79.0%) 353 (77.8%) 481 (67.3%) 730 (74.0%) 712 (74.3%) 494 (72.8%) 272 (68.9%)
Black, n (%) 46 (10.8%) 180 (18.8%) 33 (16.1%) 193 (16.4%) 25 (11.9%) 59 (13.0%) 142 (19.9%) 180 (18.3%) 173 (18.1%) 121 (17.8%) 46 (11.6%)
Asian, n (%) 55 (12.9%) 68 (7.1%) 11 (5.4%) 112 (9.5%) 14 (6.7%) 35 (7.7%) 74 (10.3%) 55 (5.6%) 53 (5.5%) 48 (7.1%) 68 (17.2%)
BMI, kg m− 2, mean 27.4 32.6 32.3 30.8 30.4 31.2 31.1 32.9 32.8 32.2 26.2
Obesity
(BMI⩾ 30 kg m− 2),
n (%)
109 (25.6%) 619 (64.8%) 129 (62.9%) 599 (50.9%) 97 (46.2%) 242 (53.3%) 389 (54.4%) 728 (73.8%) 700 (73.1%) 437 (64.4%) 393 (99.5%)
SBP, mm Hg, mean 158.8 155.5 159.1 156.1 157.1 156.3 156.5 156.3 156.3 156.1 157.1
DBP, mm Hg, mean 99.3 99.7 99.3 99.6 99.2 99.9 99.4 99.5 99.5 99.5 99.6
Abbreviations: BMI, body mass index; CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein;
SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.
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comparative purposes. Descriptive analyses were performed for the
change from baseline in mean SBP and DBP and for control rates utilising
the criteria described above. DBP and SBP changes from baseline are
presented as least squares means, calculated using analysis of covariance,
with treatment, (pooled) centres, BP and age at baseline as covariates.
Missing values are imputed by the last observation carried forward
approach.
Safety analyses include all randomised subjects who took at least one
dose of study drug. Participants with treatment-emergent AEs are analysed
according to pooled treatment groups: nifedipine GITS–candesartan
cilexetil combination, nifedipine GITS or candesartan cilexetil monother-
apy, or placebo, as in the main DISTINCT study.11
Analyses were performed using SAS software 9.2 (SAS Institute Inc., Cary,
NC, USA).
RESULTS
Demographics
A total of 2817 patients were screened and 1381 (49.0%) were
randomised to treatment in the main DISTINCT study
(Supplementary Materials Supplementary Figure 1).11 Of
these patients, 30.8% (n= 426) had renal impairment of any
grade (eGFRo90 ml min− 1), including 3.6% (n= 50) with
moderate/severe renal impairment (eGFRo60 ml min− 1); 14.8%
(n= 205) had T2DM; 15.2% (n= 210) had hypercholesterolaemia
and 71.4% (n= 986) had CV risk factors. Baseline characteristics of
patients with renal impairment, T2DM, hypercholesterolaemia and
CV risk factors are provided in Table 1. Approximately one-half of
high-risk participants were male, with an age range of 53.7–61.6
years and approximately one-half in each group were obese. The
high-risk populations were generally well matched in baseline
characteristics with the main DISTINCT study population11 and
with patient subgroups without the high-risk conditions, although
the subgroup with renal impairment was older (mean 62 vs 51
years), had lower BMI (27 vs 33 kg m− 2) and included a larger
proportion of Asian and fewer Black participants than the
subgroup without renal impairment (Table 1).
Efficacy
The efficacy analysis set in the main DISTINCT study included 1362
individuals.11 Of this population, the high-risk participants
included 422 with renal impairment of any grade
(eGFRo90 ml min− 1), including 50 with moderate/severe renal
impairment (eGFRo60 ml min− 1), 202 with T2DM, 206 with
hypercholesterolaemia and 971 with CV risk factors. These
subgroups were investigated for efficacy in the current analyses.
Additional subgroup analyses according to gender (male, n= 788),
and tertiles of age (o55 years, n= 701; 55–64, n= 463; ⩾ 65,
n= 198) and BMI (o25 kg m− 2, n= 172; 25–29, n= 467; ⩾ 30,
n= 719) are also included in the Supplementary Materials.
BP changes. As reported for the main DISTINCT study
population,11 mean changes in SBP/DBP in high-risk participants
were overall greater with combination therapy than respective
monotherapies or placebo, with indicators of a dose–response
effect (Table 2). In general, consistent trends were observed
between high-risk participants and respective non-high-risk
groups in terms of greater BP reduction in combination therapy
compared with the respective monotherapies or placebo (Table 2).
Pooled treatment analyses demonstrated that early SBP/DBP
reductions (that is, within the first 2 weeks of treatment) were
superior for combination therapy vs each monotherapy in all
high-risk groups, including those with renal impairment of any
grade (Figure 1a), T2DM (Figure 1b), hypercholesterolaemia
(Figure 1c) and any CV risk factors (Figure 1d). These group
differences were sustained for the study duration.T
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Figure 1. Least squares mean change in SBP/DBP (mm Hg) during 8 weeks of treatment with nifedipine GITS (N20, 30, 60) and/or candesartan
cilexetil (C4, 8, 16, 32) in individuals with (a) renal impairment (baseline eGFRo90 ml min− 1), (b) T2DM, (c) hypercholesterolaemia (total
cholesterol4240 mg dl− 1) or (d) any CV risk factors (T2DM or BMI⩾ 30 kg m− 2 or LDL⩾ 130 mg dl− 1). Abbreviations: BMI, body mass index;
BP, blood pressure; C, candesartan cilexetil; CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate;
LDL, low-density lipoprotein; N, nifedipine GITS; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.
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BP control rates. In all high-risk participants, 8-week BP control
rates (using ESH/ESC 2013 guidelines) were generally higher with
combination therapy than monotherapies or placebo, with
indicators of a dose–response effect (Table 3, Figure 2). Findings
were comparable using the stricter, prespecified definition for BP
control of o130/80 mm Hg.
In pooled treatment analyses, combination therapy was
associated with earlier BP control compared with monotherapies
in participants with renal impairment of any grade, T2DM,
hypercholesterolaemia and CV risk factors (Figure 3a–d). These
improvements were maintained throughout the study, consistent
with the main outcomes.
Descriptive subgroup analyses based on gender and tertiles of
both age and BMI demonstrated a similar greater treatment
effect for combination therapy vs placebo and respective
monotherapies for BP changes and BP control, as above, across
patient groups (Supplementary Materials Supplementary Tables 1
and 2).
Safety
The safety analysis set in the main DISTINCT study included 1381
individuals.11 Of this population, 426 had renal impairment of any
grade (eGFRo90 ml min− 1), including 50 with moderate/severe
renal impairment (eGFRo60 ml min− 1), 205 had T2DM, 210 had
hypercholesterolaemia and 986 had CV risk factors. These
subgroups were investigated for safety in the current analyses.
At least one treatment-emergent AE was reported in 141/426
participants (33.1%) with renal impairment of any grade, 61/205
(29.8%) with T2DM, 64/210 (30.5%) with hypercholesterolaemia
and 382/986 (38.7%) with CV risk factors (Table 4). The treatment-
emergent AEs led to discontinuation of study drug in 12 (2.8%)
participants with renal impairment of any grade, 4 (2.0%) with
T2DM, 5 (2.4%) with hypercholesterolaemia and 18 (1.8%) with CV
risk factors. In pooled treatment analyses, the highest rate of
treatment-emergent AEs was consistently in high-risk patients
taking nifedipine GITS monotherapy compared with combination
therapy (40.2% vs 36.2% of those with renal impairment of any
grade, 34.9% vs 34.0% with T2DM, 34.9% vs 29.7% with
hypercholesterolaemia and 43.7% vs 41.9% with CV risk factors).
It is notable that treatment-emergent AEs in these subgroups
appeared to occur at generally similar or lower rates than in
participants without the high-risk conditions (Table 4).
Vasodilatory treatment-emergent AEs occurred at a lower rate
with combination therapy vs nifedipine GITS monotherapy in all
high-risk participants (renal impairment of any grade: 12.2% vs
23.0%; T2DM: 14.4% vs 18.6%; hypercholesterolaemia: 13.9% vs
18.6%; any CV risk factors: 20.3% vs 25.1%) (Table 4). These rates
were also, overall, lower among the high-risk participants
compared with the non-high-risk participants. Incidences of
oedema during 8-week treatment were consistently lower with
combination therapy than nifedipine GITS monotherapy at all
times for each high-risk subgroup (Figure 4a–d).
Safety analyses based on gender, age and BMI demonstrated
similar rates of total treatment-emergent AEs and vasodilatory
treatment-emergent AEs in combination therapy, respective
monotherapies and placebo groups, when compared with the
main study population, without evident differences between
males or females, tertiles of age or BMI (Supplementary Materials
Supplementary Table 3).
DISCUSSION
These subgroup analyses of DISTINCT show that nifedipine GITS–
candesartan cilexetil combinations are more effective than
respective monotherapies or placebo for BP lowering in high-
risk populations, including those with renal impairment, diabetes,
hypercholesterolaemia or CV risk factors. Combination therapyT
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was associated with greater and earlier SBP/DBP reductions and
increased BP control (regardless of the cutoff used) compared
with respective monotherapies and these effects were sustained
throughout the 8-week study. The magnitude of SBP/DBP
lowering in these high-risk subgroups was broadly similar to the
reductions observed in the main DISTINCT study and in individuals
without these risk factors.11 These findings also applied to
subgroup analyses based on gender, age and BMI.
The presence of renal impairment, T2DM, hyper-
cholesterolaemia and obesity elevates the risk for CV events and
for further decline of renal function in hypertensive patients,
especially among older patients.2 Angiotensin-converting enzyme
(ACE) inhibitors and ARBs are the preferred drug classes for
antihypertensive therapy in patients with diabetes and renal
impairment, given their superior renoprotective effects
compared to other antihypertensive classes.22 Several randomised
controlled trials have indicated more effective reductions in
microalbuminuria or proteinuria using RAS inhibitors compared
with other antihypertensive agents or placebo.12 Various studies
across different patient subgroups, including those with T2DM,
CKD and diabetic nephropathy, have found a consistent reduction
in urinary protein excretion endpoints associated with ARB
use.23–25 Recent guidelines recommend combination therapy for
high-risk patients to achieve target BP.2 Randomised, double-blind
trials have demonstrated the antihypertensive efficacy of
candesartan cilexetil26 and CCB–ARB combination27 in diabetic
populations. However, few randomised studies have investigated
the effects of nifedipine GITS in high-risk populations with renal
impairment or diabetes.28,29 The positive findings in this study of
greater and earlier BP reductions in both high-risk groups
supports the literature on the additive effects of combination
therapy for hypertension.
A number of studies have also highlighted the CV benefits of
CCB and RAS inhibitor therapy in high-risk patients. The INSIGHT
study of 1302 individuals with hypertension and diabetes
found similar incidence rates of primary CV outcomes (CV death,
myocardial infarction, heart failure, stroke) and mean BP
reductions for CCB (nifedipine GITS) and thiazide (co-amilozide)
treatment.29 However, composite secondary outcomes (all-cause
death, vascular-related death and non-vascular-related death)
l l
l l l l
l l
l l l l
l l
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Figure 2. Stratified BP control rates (ESH/ESC 2013:o140/85 mm Hg for diabetes patients in each treatment group and o140/90 mm Hg for
all other patients, (%) achieved at week 8 in high-risk individuals treated with nifedipine GITS (N20, 30, 60) and/or candesartan cilexetil (C4, 8,
16, 32) or placebo. (a) Renal impairment (baseline eGFRo90 ml min− 1), (b) T2DM, (c) hypercholesterolaemia (total cholesterol4240 mg dl− 1)
or (d) any CV risk factors (T2DM or BMI ⩾30 kg m− 2 or LDL ⩾130 mg dl− 1). Arrow indicates dose group with highest BP control. Abbreviations:
BMI, body mass index; BP, blood pressure; C, candesartan cilexetil; CV, cardiovascular; eGFR, estimated glomerular filtration rate; LDL, low-
density lipoprotein; N, nifedipine GITS; T2DM, type 2 diabetes mellitus.
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were significantly lower with nifedipine GITS than co-amilozide
(14.2% vs 18.7%; P= 0.03). A post hoc analysis of the ACTION trial
showed that adding nifedipine GITS to an existing antihyperten-
sive regimen reduced BP by an average of – 6/– 3 mm Hg in
patients with diabetes and hypertension with controlled BP
(mean= 140.7/79.8 mm Hg) at baseline.30 The ACCOMPLISH trial
compared the combination of an ACE inhibitor (benazepril) with
either a CCB (amlodipine) or thiazide diuretic (hydrochlorothia-
zide) and found superior outcomes with the CCB–ACE inhibitor
combination in terms of reduced CV deaths, nonfatal myocardial
infarction and nonfatal stroke31 and a significant reduction in CKD
progression.32 A subgroup analysis also found a significant
reduction in the risk of a composite of CV outcomes among
patients with diabetes receiving CCB–ACE inhibitor treatment
(compared with diuretic–ACE inhibitor).33
Hypertension, glucose intolerance, central obesity and hyper-
cholesterolaemia are components of a risk factor cluster (termed
‘metabolic syndrome’) for CV disease and T2DM.21 However, some
of these risk factors have been found to impact differently
according to gender, for example, greater CV heart disease
mortality in women with diabetes compared to men.34 Given that
more than a third of the DISTINCT study sample presented with at
least one CV risk factor, this supports the literature that most of
the hypertensive population rarely presents with elevated BP in
isolation.2 Recent ESC/EAS guidelines recommend LDL
cholesterol-targeted interventions in hypertensive patients with
CV risks, that is, those with metabolic syndrome, as these
populations present a higher risk of CV diseases than the
general population.35 The ASCOT-LLA trial demonstrated
improved outcomes with the addition of a statin to the treatment
regime for an average of 3 years, including reductions in major CV
events and a lowering of total serum cholesterol.36
Nifedipine GITS–candesartan cilexetil combination therapy was
associated in the current analyses with a lower incidence of
vasodilatory treatment–emergent AEs compared with nifedipine
GITS monotherapy, with an approximate halving of these
side-effects for participants with renal impairment and a reduction
of approximately one quarter for the diabetes, hypercholester-
olaemia and CV risk factor subgroups. These improvements
were largely due to reductions in the incidence of headache in
high-risk subgroups, except for patients with hypercholesterolae-
mia. The incidence of oedema was also lower with combination
therapy vs nifedipine GITS monotherapy in participants with
renal impairment and hypercholesterolaemia, although not in
those with diabetes or CV risk factors. CCB-associated oedema
is a known side-effect of vasodilation, caused by increased
intracapillary pressure which results in leakage of fluid into
dependent soft tissue. This can be alleviated by concomitant use
of a RAS blocker, which induces post-capillary venular relaxation
therefore reducing CCV-related intracapillary pressure and capil-
lary leakage.37 However, given the relatively common occurrence
of a persistent dry cough with ACE inhibitors, ARBs may present
a better tolerability profile with similar antihypertensive
effectiveness.38
These analyses have some limitations. First, DISTINCT was not
powered to enable subgroup comparisons, precluding meaningful
statistical analyses. Second, the definition of BP control in the
main DISTINCT study used a target of o140/90 mm Hg for the
overall population and o130/80 mm Hg for those with renal
impairment and/or diabetes.11 These definitions were included in
the study protocol ahead of updates in the ESH/ESC (2013)
guidelines, which now recommend a target of o140/90 mm Hg
in patients with renal dysfunction and o140/85 mm Hg in those
with diabetes. (Notably, there remains a lack of agreement on
adopting less-aggressive BP targets, given the evidence from
l l
l l
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Figure 3. Stratified BP control rate (ESH/ESC 2013 guidelines:o140/85 mm Hg for patients with diabetes in each treatment group,
o140/90 mm Hg for all other patients) during 8 weeks of treatment with nifedipine GITS (N20, 30, 60) and/or candesartan cilexetil (C4, 8, 16,
32) in individuals with (a) renal impairment of any grade (baseline eGFRo90 ml min− 1), (b) T2DM, (c) hypercholesterolaemia (total
cholesterol4240 mg dl− 1) or (d) any CV risk factors (T2DM or BMI⩾ 30 kg m− 2 or LDL⩾ 130 mg dl− 1. Abbreviations: BMI, body mass index;
BP, blood pressure; C, candesartan cilexetil; CV, cardiovascular; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein;
N, nifedipine GITS; T2DM, type 2 diabetes mellitus.
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Table 4. Treatment-emergent AEs, n/N (%) by pooled treatment with nifedipine GITS (N20, 30, 60 mg) and/or candesartan cilexetil (C4, 8, 16, 32 mg)
or placebo in high-risk and non-high-risk individuals treated for 8 weeks (safety analysis set)
Pooled
treatment group
Renal impairment (baseline
eGFRo90 ml min− 1)
T2DM Hypercholesterolaemia (total
cholesterol4240 mg dl− 1)
CV risk factor(s) (T2DM or BMI⩾ 30 kg m− 2 or
LDL⩾ 130 mg dl− 1)
Yes (N= 426) No (N= 955) Yes (N= 205) No
(N= 1176)
4240
(N= 210)
200–240
(N= 454)
o200
(N= 715)
1–3 (N= 986) 1–2 (N= 958) 1 (N= 679) None
(N= 395)
Any treatment-emergent AE
Total 141 (33.1%) 395 (41.4%) 61 (29.8%) 475
(40.4%)
64 (30.5%) 176 (38.8%) 296 (41.4%) 382 (38.7%) 375 (39.1%) 277 (40.8%) 154 (39.0%)
Placebo 3/27 (11.1%) 22/61 (36.1%) 2/14 (14.3%) 23/74
(31.1%)
3/14
(21.4%)
5/28 (17.9%) 17/46 (37.0%) 19/70 (27.1%) 19/69 (27.5%) 13/47 (27.7%) 6/18
(33.3%)
C 32/116
(27.6%)
78/230
(33.9%)
11/51
(21.6%)
99/295
(33.6%)
16/52
(30.8%)
33/104
(31.7%)
61/188
(32.4%)
79/246
(32.1%)
77/239
(32.2%)
53/162
(32.7%)
31/100
(31.0%)
N 35/87
(40.2%)
74/167
(44.3%)
15/43
(34.9%)
94/211
(44.5%)
15/43
(34.9%)
41/83
(49.4%)
53/128
(41.4%)
80/183
(43.7%)
77/174
(44.3%)
63/132
(47.7%)
29/71
(40.8%)
NC 71/196
(36.2%)
221/497
(44.5%)
33/97
(34.0%)
259/596
(43.5%)
30/101
(29.7%)
97/239
(40.6%)
165/353
(46.7%)
204/487
(41.9%)
202/476
(42.4%)
148/338
(43.8%)
88/206
(42.7%)
Any study drug-related treatment-emergent AE
Placebo 2/27
(7.4%)
7/61
(11.5%)
1/14
(7.1%)
8/74
(10.8%)
1/14
(7.1%)
0/28 8/46
(17.4%)
5/70
(7.1%)
5/69
(7.2%)
3/47
(6.4%)
4/18
(22.2%)
C 7/116
(6.0%)
29/230
(12.6%)
2/51
(3.9%)
34/295
(11.5%)
7/52
(13.5%)
13/104
(12.5%)
16/188
(8.5%)
24/246
(9.8%)
22/239
(9.2%)
16/162
(9.9%)
12/100
(12.0%)
N 19/87
(21.8%)
33/167
(19.8%)
5/43 (11.6%) 47/211
(22.3%)
9/43
(20.9%)
20/83
(24.1%)
23/128
(18.0%)
37/183
(20.2%)
35/174
(20.1%)
29/132
(22.0%)
15/71
(21.1%)
NC 34/196
(17.3%)
93/497
(18.7%)
11/97
(11.3%)
116/596
(19.5%)
18/101
(17.8%)
41/239
(17.2%)
68/353
(19.3%)
94/487
(19.3%)
94/476
(19.7%)
70/338
(20.7%)
33/206
(16.0%)
Discontinuations due to treatment-emergent AEs
Placebo 0/27 1/61 (1.6%) 0/14 1/74 (1.4%) 0/14 0/28 1/46
(2.2%)
0/70 0/69 0/47 1/18
(5.6%)
C 0/116 3/230 (1.3%) 0/51 3/295
(1.0%)
1/52
(1.9%)
0/104 2/188
(1.1%)
3/246
(1.2%)
3/239
(1.3%)
3/162
(1.9%)
0/100
N 5/87
(5.7%)
5/167
(3.0%)
1/43
(2.3%)
9/211
(4.3%)
0/43 4/83
(4.8%)
6/128
(4.7%)
5/183
(2.7%)
5/174
(2.9%)
4/132
(3.0%)
5/71
(7.0%)
NC 7/196 (3.6%) 13/497 (2.6%) 3/97 (3.1%) 17/596
(2.9%)
4/101
(4.0%)
7/239
(2.9%)
9/353
(2.5%)
10/487
(2.1%)
10/476
(2.1%)
9/338
(2.7%)
10/206
(4.9%)
Any vasodilatory treatment-emergent AE
Placebo 1/27
(3.7%)
9/61
(14.8%)
2/14
(14.3%)
8/74
(10.8%)
2/14
(14.3%)
1/28
(3.6%)
7/46
(15.2%)
7/70
(10.0%)
7/69
(10.1%)
3/47
(6.4%)
3/18
(16.7%)
C 6/116
(5.2%)
35/230
(15.2%)
6/51
(11.8%)
35/295
(11.9%)
5/52
(9.6%)
14/104
(13.5%)
22/188
(11.7%)
32/246
(13.0%)
30/239
(12.6%)
22/162
(13.6%)
9/100
(9.0%)
N 20/87
(23.0%)
40/167
(24.0%)
8/43
(18.6%)
52/211
(24.6%)
8/43
(18.6%)
28/83
(33.7%)
24/128
(18.8%)
46/183
(25.1%)
44/174
(25.3%)
35/132
(26.5%)
14/71
(19.7%)
NC 24/196
(12.2%)
103/497
(20.7%)
14/97
(14.4%)
113/596
(19.0%)
14/101
(13.9%)
38/239
(15.9%)
75/353
(21.2%)
99/487
(20.3%)
99/476
(20.8%)
72/338
(21.3%)
28/206
(13.6%)
Flushing
Placebo 0/27 0/61 0/14 0/74 0/14 0/28 0/46 0/70 0/69 0/47 0/18
C 0/116 0/230 0/51 0/295 0/52 0/104 0/188 0/246 0/239 0/162 0/100
N 0/87 1/167 (0.6%) 0/43 1/211
(0.5%)
0/43 1/83 (1.2%) 0/128 1/183 (0.5%) 1/174 (0.6%) 1/132 (0.8%) 0/71
NC 0/196 6/497 (1.2%) 0/97 6/596
(1.0%)
0/101 5/239 (2.1%) 1/353 (0.3%) 4/487 (0.8%) 4/476 (0.8%) 3/338 (0.9%) 2/206
(1.0%)
Headache
Placebo 1/27 (3.7%) 5/61 (8.2%) 1/14 (7.1%) 5/74 (6.8%) 1/14
(7.1%)
1/28 (3.6%) 4/46 (8.7%) 3/70 (4.3%) 3/69 (4.3%) 1/47 (2.1%) 3/18
(16.7%)
C 0/116 12/230 (5.2%) 1/51 (2.0%) 11/295
(3.7%)
0/52 6/104 (5.8%) 6/188 (3.2%) 9.246 (3.7%) 9/239 (3.8%) 8/162 (4.9%) 3/100
(3.0%)
N 8/87
(9.2%)
20/167
(12.0%)
4/43
(9.3%)
24/211
(11.4%)
2/43
(4.7%)
14/83
(16.9%)
12/128
(9.4%)
20/183
(10.9%)
20/174
(11.5%)
14/132
(10.6%)
8/71
(11.3%)
NC 6/196
(3.1%)
32/497
(6.4%)
2/97
(2.1%)
36/596
(6.0%)
5/101
(5.0%)
35/454
(7.7%)
19/353
(5.4%)
27/487
(5.5%)
27/476
(5.7%)
22/338
(6.5%)
11/206
(5.3%)
Oedema
Placebo 0/27 4/61
(6.6%)
1/14
(7.1%)
3/74 (4.1%) 1/14
(7.1%)
0/28 3/46
(6.5%)
4/70
(5.7%)
4/69
(5.8%)
2/47
(4.3%)
0/18
C 6/116
(5.2%)
24/230
(10.4%)
5/51
(9.8%)
25/295
(8.5%)
5/52
(9.6%)
9/104
(8.7%)
16/188
(8.5%)
24/246
(9.8%)
22/239
(9.2%)
15/162
(9.3%)
6/100
(6.0%)
N 14/87
(16.1%)
22/167
(13.2%)
5/43 (11.6%) 31/211
(14.7%)
6/43
(14.0%)
17/83
(20.5%)
13/128
(10.2%)
28/183
(15.3%)
26/174
(14.9%)
21/132
(15.9%)
8/71
(11.3%)
NC 19/196
(9.7%)
70/497
(14.1%)
12/97
(12.4%)
77/596
(12.9%)
10/101
(9.9%)
22/239
(9.2%)
57/353
(16.1%)
74/487
(15.2%)
74/476
(15.5%)
52/338
(15.4%)
15/206
(7.3%)
Abbreviations: AE, adverse event; BMI, body mass index; C, candesartan cilexetil; CV, cardiovascular; eGFR, estimated glomerular filtration rate; LDL, low-density
lipoprotein; N, nifedipine GITS; T2DM, type 2 diabetes mellitus.
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clinical trials that renal and CV protection are increased by more
intensive BP lowering.7) For these reasons, the current analyses
include control rates using both the updated ESH/ESC
recommendations (o140/85 mm Hg for patients with diabetes
and o140/90 mm Hg for other high-risk groups) and the
prespecified target (o130/80 mm Hg for patients with renal
failure and diabetes). The DISTINCT study had an 8-week duration
and therefore does not provide information on long-term efficacy
and safety. In addition, although analyses of specific high-risk
groups (that is, renal impairment and T2DM) were prespecified in
the study protocol, the other subgroup analyses (hypercholester-
olaemia and presence of CV risk factors) were performed
post hoc.
In summary, this sub-analysis of DISTINCT is the first study to
examine the effects of nifedipine GITS–candesartan cilexetil in
various dose combinations in high-risk populations, including
those with renal impairment, T2DM, hypercholesterolaemia or CV
risk factors. Consistent with the main outcomes of DISTINCT, these
analyses demonstrate that combination therapy is associated with
greater reductions in BP and higher control rates in all high-risk
subgroups. The combination therapy was well tolerated in
these high-risk groups, with a lower incidence of vasodilatory
side-effects than nifedipine GITS monotherapy.
What is known about this topic?
● Guidelines recommend initial combination therapy for individuals
with hypertension and comorbidities with increased CV risks.
● RAS blockers and β-blockers have shown beneficial renal and
metabolic outcomes.
What this study adds?
● This post hoc analysis of high-risk participants with hypertension in
the DISTINCT trial demonstrated the superior efficacy of nifedipine
GITS–ARB combination therapy, compared with respective
monotherapies and placebo.
● The nifedipine GITS–ARB combination therapy was well tolerated
with a better vasodilatory side-effect profile compared with
nifedipine GITS monotherapy in high-risk participants, as in all
patients in the main DISTINCT trial.
I I
I I
l l
l l
Figure 4. Incidence rate of oedema during 8 weeks of treatment with nifedipine GITS (N20, 30, 60) and/or candesartan cilexetil (C4, 8, 16, 32) in
individuals with (a) renal impairment (baseline eGFRo90 ml min− 1), (b) T2DM, (c) hypercholesterolaemia (total cholesterol4240 mg dl− 1)
or (d) any CV risk factors (T2DM or BMI⩾ 30 kg m− 2 or LDL⩾ 130 mg dl− 1). Abbreviations: BMI, body mass index; C, candesartan
cilexetil; CV, cardiovascular; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; N, nifedipine GITS; T2DM, type 2
diabetes mellitus.
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